BIOMAT Database Logo BIOMAT Database Logo

Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. 1992

M C Robson, and L G Phillips, and A Thomason, and B W Altrock, and P C Pence, and J P Heggers, and A F Johnston, and T P McHugh, and M S Anthony, and L E Robson
Department of Surgery, University of Texas Medical Branch, Galveston 77555.

A randomized phase I/II double-blind, placebo-controlled study was designed to evaluate 1, 10, and 100 micrograms/ml (0.01, 0.1, and 1.0 micrograms/cm2) recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) applied topically to chronic pressure ulcers for 28 days. Twenty patients were enrolled and completed the trial. No toxicities were associated with rPDGF-BB treatment. Patients treated with 100 micrograms/ml of rPDGF-BB had a pronounced healing response compared with placebo-treated patients. By day 29, ulcers treated with 100 micrograms/ml of rPDGF-BB were smaller in remaining size compared with those of placebo-treated patients when the following specific parameters were measured: percentage of initial depth (14.1 +/- 7.4 vs. 34.9 +/- 6.7) and percentage of initial volume (6.4 +/- 4.0 vs. 21.8 +/- 5.6). Histological analyses of biopsies revealed active wound healing processes in all groups with no disruption in the normal healing sequence in rPDGF-BB-treated wounds. The results of this small, descriptive study suggest rPDGF-BB is a potent vulnerary agent for accelerating soft-tissue repair, warranting further study.

UI MeSH Term Description Entries
D010982 Platelet-Derived Growth Factor Mitogenic peptide growth hormone carried in the alpha-granules of platelets. It is released when platelets adhere to traumatized tissues. Connective tissue cells near the traumatized region respond by initiating the process of replication. Platelet Derived Growth Factor,Factor, Platelet-Derived Growth,Growth Factor, Platelet-Derived
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003668 Pressure Ulcer An ulceration caused by prolonged pressure on the SKIN and TISSUES when one stays in one position for a long period of time, such as lying in bed. The bony areas of the body are the most frequently affected sites which become ischemic (ISCHEMIA) under sustained and constant pressure. Bedsore,Decubitus Sore,Decubitus Ulcer,Pressure Injury,Pressure Sore,Bed Sores,Bed Sore,Bedsores,Decubitus Sores,Decubitus Ulcers,Injury, Pressure,Pressure Injuries,Pressure Sores,Pressure Ulcers,Sore, Bed,Sore, Decubitus,Sore, Pressure,Ulcer, Decubitus,Ulcer, Pressure
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D014945 Wound Healing Restoration of integrity to traumatized tissue. Healing, Wound,Healings, Wound,Wound Healings

Related Publications

M C Robson, and L G Phillips, and A Thomason, and B W Altrock, and P C Pence, and J P Heggers, and A F Johnston, and T P McHugh, and M S Anthony, and L E Robson
Re: Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers.
February 1993, Annals of plastic surgery,
M C Robson, and L G Phillips, and A Thomason, and B W Altrock, and P C Pence, and J P Heggers, and A F Johnston, and T P McHugh, and M S Anthony, and L E Robson
Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB.
December 1994, The American journal of pathology,
M C Robson, and L G Phillips, and A Thomason, and B W Altrock, and P C Pence, and J P Heggers, and A F Johnston, and T P McHugh, and M S Anthony, and L E Robson
Successful treatment of chronic wound in Klippel-Trenaunay syndrome with recombinant human platelet-derived growth factor-BB.
June 2002, Plastic and reconstructive surgery,
M C Robson, and L G Phillips, and A Thomason, and B W Altrock, and P C Pence, and J P Heggers, and A F Johnston, and T P McHugh, and M S Anthony, and L E Robson
Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
January 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society,
M C Robson, and L G Phillips, and A Thomason, and B W Altrock, and P C Pence, and J P Heggers, and A F Johnston, and T P McHugh, and M S Anthony, and L E Robson
A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.
February 1994, Archives of surgery (Chicago, Ill. : 1960),
M C Robson, and L G Phillips, and A Thomason, and B W Altrock, and P C Pence, and J P Heggers, and A F Johnston, and T P McHugh, and M S Anthony, and L E Robson
Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
January 1999, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons,
M C Robson, and L G Phillips, and A Thomason, and B W Altrock, and P C Pence, and J P Heggers, and A F Johnston, and T P McHugh, and M S Anthony, and L E Robson
Recombinant human platelet-derived growth factor BB for reconstruction of human large extraction site defects.
January 2014, The International journal of periodontics & restorative dentistry,
M C Robson, and L G Phillips, and A Thomason, and B W Altrock, and P C Pence, and J P Heggers, and A F Johnston, and T P McHugh, and M S Anthony, and L E Robson
Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
June 2006, Plastic and reconstructive surgery,
M C Robson, and L G Phillips, and A Thomason, and B W Altrock, and P C Pence, and J P Heggers, and A F Johnston, and T P McHugh, and M S Anthony, and L E Robson
Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers.
January 2005, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society,
M C Robson, and L G Phillips, and A Thomason, and B W Altrock, and P C Pence, and J P Heggers, and A F Johnston, and T P McHugh, and M S Anthony, and L E Robson
Tissue engineering with recombinant human platelet-derived growth factor BB for implant site development.
March 2011, Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995),
Copied contents to your clipboard!